Targets › CD47
8 programs from 7 companies in 28 trials: 15 Phase 1, 11 Phase 2, 2 Phase 3; Oncology, Hematology; next expected readout Dec 2026.
Adhesive protein that mediates cell-to-cell interactions. Acts as a receptor for thrombospondin THBS1 and as modulator of integrin signaling through the activation of heterotrimeric G proteins. (UniProt, Q08722)
Open in Phaseline: the race on CD47, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Akeso | AK117 anti-CD47 antibody | CD47 | Phase 3 | Head and Neck Squamous Cell Carcinoma; Higher-risk Myelodysplastic Syndromes; Metastatic Triple-negative Breast Cancer; Resectable Gastric or Gastroesophageal Junction Adenocarcinoma … | Dec 2026 |
| Suzhou Suncadia Biopharmaceuticals | SHR-A1912 CD47 antagonist/signal regulatory protein alpha (SIRPα) blockade | CD47 | Phase 3 | Diffuse Large B-cell Lymphoma | Mar 2027 |
| ALX Oncology | Evorpacept (ALX148) Leukocyte surface antigen CD47 inhibitor | CD47 | Phase 2 | Gastric Cancer; Head and Neck Cancer; Breast Cancer, Metastatic; Ovarian Cancer … | Dec 2027 |
| FBD Biologics | HCB101 SIRPα-Fc fusion protein targeting CD47 | SIRPA, CD47 | Phase 1 | Advanced Solid Tumor; Solid Cancer; CRC; HNSCC | May 2027 |
| Ono Pharmaceutical | Magrolimab (ONO-7913) Leukocyte surface antigen CD47 inhibitor | CD47 | Phase 1 | Metastatic Pancreatic Cancer; Unresectable Colorectal Cancer | Jun 2027 |
| Phanes Therapeutics | Peluntamig (PT217) Bispecific antibody against DLL3 and CD47 | DLL3, CD47 | Phase 1 | Small Cell Lung Cancer (SCLC) | Dec 2027 |
| Phanes Therapeutics | Spevatamig (PT886) Bispecific antibody targeting Claudin 18.2 and CD47 | CLDN18, CD47 | Phase 1 | Gastric or Gastroesophageal Junction Adenocarcinoma | Dec 2027 |
| Pfizer | Maplirpacept CD47-SIRP alpha-directed immune checkpoint inhibitor | CD47 | Phase 1 | Multiple Myeloma | Feb 2028 |
Head and Neck Cancer (2) Head and Neck Squamous Cell Carcinoma (1) Higher-risk Myelodysplastic Syndromes (1) Metastatic Triple-negative Breast Cancer (1) Resectable Gastric or Gastroesophageal Junction Adenocarcinoma (1) Extensive-stage Small Cell Lung Cancer (ES-SCLC) (1) Metastatic Colorectal Cancer (1) Acute Myeloid Leukemia (1) Myelodysplastic Syndrome (1) Advanced Malignant Tumors (1) Classic Hodgkin Lymphoma (1) Gastric Cancer (1)
mixed (7), small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.